3D PRINTING TECHNOLOGIES AND ARTIFICIAL INTELLIGENCE IN PERSONALIZED SOLID ORAL DOSAGE FORM DESIGN: CURRENT PROGRESS AND FUTURE PERSPECTIVES

Three-dimensional (3D) printing is transforming oral drug delivery by enabling the precise fabrication of solid dosage forms with patient-specific doses, geometries, and release profiles, thus supporting the paradigm of personalized medicine. Unlike conventional batch manufacturing, additive manufacturing techniques such as fused deposition modeling, binder jetting, and allow rapid, on-demand production of complex tablets and polypills, including multi-layer and compartmentalized structures that can combine several active pharmaceutical ingredients (APIs) with distinct release kinetics in a single unit. This flexibility is particularly valuable for populations requiring fine dose titration or simplified regimens, such as paediatric, geriatric, and polymorbid patients, and for chronic or complex diseases like epilepsy, diabetes, and cardiovascular disorders Artificial intelligence (AI) significantly amplifies this potential by learning quantitative relationships between formulation composition, printing parameters, and in vitro performance, then using these models to automatically propose tablet architectures that meet predefined therapeutic or pharmacokinetic targets.AI-driven tools can predict excipient–drug compatibility, optimize printing conditions, and implement real-time monitoring and adaptive control, thereby reducing trial-and-error, enhancing process robustness, and enabling consistent quality in both centralized and point-of-care manufacturing settings. Despite these advantages, widespread adoption is constrained by challenges in standardizing materials and printers, ensuring long- term stability and reproducibility, and the absence of harmonized regulatory frameworks tailored to decentralized, small-batch production. Continuing integration of Quality by Design principles, digital quality control, and AI-based decision support is essential to translate AI-guided 3D printing of oral dosage forms from experimental platforms into routine, clinically integrated personalized therapy.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-01-16
DOI
https://doi.org/10.5281/zenodo.18265425
Primary Topic
3D Printing in Biomedical Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

3D PRINTING TECHNOLOGIES AND ARTIFICIAL INTELLIGENCE IN PERSONALIZED SOLID ORAL DOSAGE FORM DESIGN: CURRENT PROGRESS AND FUTURE PERSPECTIVES

Imran Fareeth A. M.2, Vignesh M.1*, Dr. Selvaraju K.3, Alex Pandiyan J.2, Dhanush Narayanan R.2
Zenodo (CERN European Organization for Nuclear Research)
3D Printing in Biomedical Research
article

3D PRINTING TECHNOLOGIES AND ARTIFICIAL INTELLIGENCE IN PERSONALIZED SOLID ORAL DOSAGE FORM DESIGN: CURRENT PROGRESS AND FUTURE PERSPECTIVES

Imran Fareeth A. M.2, Vignesh M.1*, Dr. Selvaraju K.3, Alex Pandiyan J.2, Dhanush Narayanan R.2
article en

Abstract

Three-dimensional (3D) printing is transforming oral drug delivery by enabling the precise fabrication of solid dosage forms with patient-specific doses, geometries, and release profiles, thus supporting the paradigm of personalized medicine. Unlike conventional batch manufacturing, additive manufacturing techniques such as fused deposition modeling, binder jetting, and allow rapid, on-demand production of complex tablets and polypills, including multi-layer and compartmentalized structures that can combine several active pharmaceutical ingredients (APIs) with distinct release kinetics in a single unit. This flexibility is particularly valuable for populations requiring fine dose titration or simplified regimens, such as paediatric, geriatric, and polymorbid patients, and for chronic or complex diseases like epilepsy, diabetes, and cardiovascular disorders Artificial intelligence (AI) significantly amplifies this potential by learning quantitative relationships between formulation composition, printing parameters, and in vitro performance, then using these models to automatically propose tablet architectures that meet predefined therapeutic or pharmacokinetic targets.AI-driven tools can predict excipient–drug compatibility, optimize printing conditions, and implement real-time monitoring and adaptive control, thereby reducing trial-and-error, enhancing process robustness, and enabling consistent quality in both centralized and point-of-care manufacturing settings. Despite these advantages, widespread adoption is constrained by challenges in standardizing materials and printers, ensuring long- term stability and reproducibility, and the absence of harmonized regulatory frameworks tailored to decentralized, small-batch production. Continuing integration of Quality by Design principles, digital quality control, and AI-based decision support is essential to translate AI-guided 3D printing of oral dosage forms from experimental platforms into routine, clinically integrated personalized therapy.

Zenodo (CERN European Organization for Nuclear Research)
Openalex Percentile: Top 87%
3D Printing in Biomedical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

3D PRINTING TECHNOLOGIES AND ARTIFICIAL INTELLIGENCE IN PERSONALIZED SOLID ORAL DOSAGE FORM DESIGN: CURRENT PROGRESS AND FUTURE PERSPECTIVES — Imran Fareeth A. M.2, Vignesh M.1*, Dr. Selvaraju K.3, Alex Pandiyan J.2, Dhanush Narayanan R.2 · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS